T cells are paranoid by design: they won’t fully activate just because they “see” an antigen. They require a second, independent confirmation signal—costimulation—to prevent accidental attacks on self. On Step 1, this shows up everywhere: transplant rejection, tumor immune evasion, CTLA-4 drugs, HIV, hyper-IgM, chronic granulomatous disease tie-ins (via T-cell help), and the classic “T cell becomes anergic without costimulation” vignette.
Big Picture: What Are Costimulatory Molecules?
Costimulatory molecules are receptor–ligand pairs that provide “Signal 2” (and additional tuning signals) during immune cell activation.
The classic 2-signal model (T cells)
- Signal 1 (specificity): TCR recognizes peptide presented on MHC
- Signal 2 (costimulation): ensures antigen recognition occurs in the right context (infection/danger)
- Signal 3 (cytokines): shapes differentiation (Th1/Th2/Th17/Tfh/Treg)
High-yield rule:
If a naive T cell receives Signal 1 without Signal 2 → anergy (functional unresponsiveness) or deletion/tolerance.
Core Costimulatory Pathways You Must Know
1) B7 (CD80/86) ↔ CD28 (activation)
- APC expresses: B7 (CD80/CD86)
- T cell expresses: CD28
- Result: IL-2 production, clonal expansion, survival
Where B7 comes from (Step logic):
APCs (especially dendritic cells) upregulate B7 when their PRRs (e.g., TLRs) sense microbes → links innate danger sensing to adaptive activation.
Vignette clue: “T cells fail to activate after exposure to antigen because APCs lack B7” → think impaired costimulation.
2) B7 (CD80/86) ↔ CTLA-4 (inhibition)
- CTLA-4 is upregulated after T-cell activation and is constitutively expressed on Tregs
- Binds B7 with higher affinity than CD28
- Function: “brake” at the priming phase (lymph nodes)
Clinical tie-in (HY):
- CTLA-4 inhibitor: Ipilimumab
- Boosts T-cell activation against cancer
- Causes immune-related adverse events (autoimmune-like): colitis, hepatitis, dermatitis, hypophysitis, thyroiditis
Board-style phrasing: “Checkpoint inhibitor causing severe diarrhea and colitis” → CTLA-4 (or PD-1/PD-L1) blockade.
3) CD40 (APC/B cell) ↔ CD40L (CD154 on Th cells) (help)
This is the most tested “T cell helps B cell / macrophage” interaction.
-
On B cells, CD40 signaling:
- Class switching (with cytokines)
- Germinal center formation
- Affinity maturation (with Tfh help)
-
On macrophages, CD40 signaling:
- “Licenses” macrophages—especially important in intracellular pathogens
- Works with IFN-γ from Th1 cells to enhance killing
Clinical tie-in (very HY): Hyper-IgM syndrome (X-linked)
- Defect: CD40L on Th cells
- Consequences:
- No class switching → ↑ IgM, ↓ IgG/IgA/IgE
- Absent germinal centers
- Susceptible to opportunistic infections (e.g., Pneumocystis, Cryptosporidium, CMV)
- Typical prompt: “Boy with recurrent pyogenic infections, no CD40L, high IgM, absent germinal centers.”
4) PD-1 (T cell) ↔ PD-L1/PD-L2 (inhibition in tissues)
- PD-1 is expressed on T cells (especially chronically stimulated/exhausted T cells)
- PD-L1 can be expressed on APCs and many tissues, including tumors
- Function: peripheral “brake” to reduce tissue damage; important in T-cell exhaustion (e.g., chronic viral infection)
Drugs (HY):
- Nivolumab, Pembrolizumab = anti–PD-1
- Atezolizumab, Durvalumab, Avelumab = anti–PD-L1
- Adverse effects similar to CTLA-4 inhibitors: autoimmune-like (pneumonitis, colitis, hepatitis, endocrinopathies)
Step pattern recognition: Tumor evades immune attack by expressing PD-L1 → blocking PD-1 restores T-cell function.
Costimulation: Pathophysiology & “Why It Matters”
Without costimulation: Anergy and tolerance
- In the absence of infection/danger, APCs present antigen with low B7 expression
- Naive T cells seeing antigen under these conditions become anergic
- This is a core mechanism of peripheral tolerance (prevents autoimmunity)
With costimulation: Productive immunity
- Infection → PRR signaling (TLRs, etc.) → ↑ B7 and cytokines
- T cells proliferate (IL-2), differentiate, and provide downstream help:
- Activate macrophages (Th1)
- Activate eosinophils and B cells (Th2)
- Recruit neutrophils (Th17)
- Support germinal centers (Tfh)
High-Yield Table: Signal Pairs, Cells, and Outcomes
| Pathway | Ligand (Cell) | Receptor (Cell) | Net Effect | HY Associations |
|---|---|---|---|---|
| B7 (CD80/86)–CD28 | B7 on APC | CD28 on T cell | Activates T cells (↑ IL-2) | Lack of B7 → anergy |
| B7–CTLA-4 | B7 on APC | CTLA-4 on T cell/Treg | Inhibits T-cell priming | Ipilimumab; autoimmune toxicities |
| CD40–CD40L (CD154) | CD40 on B cell/APC | CD40L on Th cell | Class switching, macrophage activation | Hyper-IgM (X-linked CD40L) |
| PD-1–PD-L1/PD-L2 | PD-L1 on tumor/APC/tissues | PD-1 on T cell | Inhibits in peripheral tissues; exhaustion | Pembrolizumab/Nivolumab; tumor evasion |
Clinical Presentation: How It Appears in Vignettes
A) “T cells don’t activate” → think missing costimulation
- Naive T cell recognizes peptide–MHC but fails to proliferate
- Lab clue: low IL-2, poor clonal expansion
- Mechanism: no B7–CD28 engagement → anergy
B) “High IgM, no class switching” → CD40L defect
- Recurrent sinopulmonary infections + opportunistic infections
- Lab: ↑ IgM, ↓ others
- Lymph node biopsy: absent germinal centers
C) “Checkpoint inhibitor side effects” → CTLA-4 or PD-1 blockade
- Patient on immunotherapy develops:
- Colitis (watery diarrhea)
- Hepatitis (↑ LFTs)
- Pneumonitis (cough, dyspnea)
- Endocrinopathies (hypophysitis, thyroiditis, adrenal insufficiency)
D) “Tumor expresses PD-L1” → immune evasion
- Reduced cytotoxic T-cell activity in the tumor microenvironment
- Responds to PD-1/PD-L1 inhibitors
Diagnosis: What You’d Actually Test (and What Step Expects)
Step-style “diagnosis” = interpret the immunology
You’re rarely ordering “B7 levels.” Instead, you infer defects based on:
- Flow cytometry markers (e.g., absent CD40L on Th cells)
- Immunoglobulin patterns (hyper-IgM profile)
- History of recurrent/opportunistic infections
- Drug exposure (checkpoint inhibitors) + autoimmune symptoms
Real-world confirmatory examples (for context)
- Hyper-IgM: flow cytometry for CD40L (CD154), genetic testing
- Checkpoint toxicity: clinical diagnosis + labs (LFTs, thyroid function), imaging for pneumonitis, colonoscopy if severe colitis
Treatment & Management (High Yield)
Hyper-IgM syndrome (CD40L deficiency)
- IVIG replacement (provides IgG)
- Prophylaxis against opportunistic infections (institution-specific; commonly TMP-SMX for Pneumocystis)
- Hematopoietic stem cell transplant can be curative in select cases
Checkpoint inhibitor toxicity
- Hold immunotherapy depending on severity
- Corticosteroids for moderate–severe immune-related adverse events
- Escalation (specialist-driven): e.g., infliximab for refractory colitis (avoid in some hepatitis settings)
Therapeutic exploitation of costimulation
- CTLA-4 and PD-1/PD-L1 inhibitors enhance anti-tumor immunity by removing inhibitory signals
Innate–Adaptive Bridge: Why APCs Control Costimulation
A common “concept integration” question is: Why doesn’t every antigen activate T cells?
- Dendritic cells sense microbes via TLRs/PRRs
- This induces:
- ↑ B7 (CD80/86)
- Cytokines that drive differentiation (Signal 3)
- Without those innate cues, antigen presentation is interpreted as “probably self” → tolerance
Translation: The innate immune system decides when the adaptive immune system is allowed to go loud.
Ultra–High-Yield Associations (Rapid Review)
- Signal 1 without Signal 2 → anergy
- B7 (CD80/86) on APC binds CD28 on T cell → activation (↑ IL-2)
- CTLA-4 competes with CD28 and turns off T cells; Ipilimumab blocks CTLA-4
- PD-1/PD-L1 suppresses T cells in tissues/tumors; Pembrolizumab/Nivolumab block PD-1
- CD40L (CD154) on Th cells is required for B-cell class switching; defect → Hyper-IgM syndrome
- Tregs use CTLA-4 as part of suppression (conceptual link to tolerance)
First Aid Cross-References (by topic area)
(Exact page numbers vary by edition—use these as “where to look” anchors.)
- T-cell activation & anergy: Immunology section on T-cell signaling (CD28/B7) and anergy
- Costimulatory molecules: tables/figures listing B7–CD28, CD40–CD40L, CTLA-4, PD-1
- Hyper-IgM syndrome: Immunodeficiencies (class switching defects; CD40L)
- Checkpoint inhibitors: Pharmacology—anticancer drugs/immunotherapy; adverse autoimmune toxicities
- T-helper subsets: Th1/Th2/Th17/Tfh cytokines (connect Signal 3 to function)
Quick Self-Check (Mini Vignettes)
-
Naive T cells exposed to antigen by resting APCs become unresponsive.
→ Missing B7–CD28 costimulation → anergy -
Boy with recurrent infections, high IgM, low IgG/IgA/IgE, absent germinal centers.
→ X-linked Hyper-IgM from CD40L defect -
Cancer patient on checkpoint therapy develops severe diarrhea and abdominal pain.
→ Immune-mediated colitis from CTLA-4 (ipilimumab) or PD-1 blockade -
Tumor biopsy shows high PD-L1 expression.
→ Tumor immune evasion; treat with anti–PD-1/PD-L1